Company Overview
Chemomab Ltd. is a clinical-stage biopharmaceutical company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.
Chemomab is making great strides with its novel anti-CCL24 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders.
CM-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action.
Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver, skin and lung fibrosis.
Recent News
-
Chemomab Announces First Patient Enrolled in Phase IIa Study of CM-101 for the Treatment of Patients with Primary Sclerosing Cholangitis
-
Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients
-
Chemomab Entered into a Definitive Reverse Merger Agreement with Anchiano Therapeutics, a NASDAQ Listed Company
Upcoming Events
-
Chemomab to participate at the BIO-Europe Spring Digital Conference | March 22-25, 2021.
-
Chemomab to present at Oppenheimer 31st Annual Healthcare Conference I March 16-18, 2021. Dr. Adi Mor, CEO virtual presentation is scheduled for Thursday, March 18, 2021 at 8:00 AM - 8:30 AM (ET).
-
Chemomab to present at H.C. Wainwright Global Life Sciences Conference I March 9-10, 2021. On-demand presentation by Dr. Adi Mor, CEO will be available through the conference.
